Hainan General Sanyang Pharmaceutical Co. Ltd.

Main study objectives: To study the pharmacokinetics of the test formulation Nicergoline Tablets (Specification: 10 mg, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.) and the reference formulation Nicergoline Tablets (Sermion®, Specification: 10 mg, produced by Pfizer Italia S.r.l., Upjohn EESV certified) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two formulations in the fasting and fed state. Secondary study objectives: To evaluate the safety of the test formulation and reference formulation of Nicergoline Tablets in healthy subjects after a single oral administration in the fasting and fed state.

Primary objective: This study aims to study the pharmacokinetic characteristics of single fasting and postprandial oral administration of tedizolid phosphate tablets (200 mg) developed and produced by Hainan General Sanyo Pharmaceutical Co., Ltd.; using Merck Sharp & Dohme LIC-licensed tedizolid phosphate tablets (Sivextro®, 200 mg) produced by Patheon Inc. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation tedizolid phosphate tablets and the reference preparation tedizolid phosphate tablets (Sivextro®) in healthy humans.

To compare the differences in the extent and rate of absorption of amoxicillin granules (125 mg/bag) provided by Hainan General Sanyo Pharmaceutical Co., Ltd. and amoxicillin dry suspension (125 mg/5 ml, trade name: Clamoxyl) certified by Laboratoire GlaxoSmithKline in healthy adults under fasting and postprandial administration conditions, and evaluate their bioequivalence. At the same time, the safety of amoxicillin granules (125 mg/bag) provided by Hainan General Sanyo Pharmaceutical Co., Ltd. and amoxicillin dry suspension (125 mg/5 ml, trade name: Clamoxyl) certified by Laboratoire GlaxoSmithKline under fasting and postprandial administration conditions was evaluated.